By Christopher Morrison
That the pace of pharmaceutical R&D externalization, and its price, have increased over the past few years is by now obvious
Reviewing Five Years of Big Pharma's Biotech Acquisitions
A review of the past five years' significant ($100mm or greater) pharma-biotech acquisitions among the industry's largest players illustrates Big Pharma's diverging M&A strategies, and why there's more to come. We examine who's buying and how much has been spent, and take a look at who has succeeded in getting value (and pipeline) for money.